top of page

Near-term Pipeline

IMMvention's mission is to create a globally accessible therapy, benefiting patients with limited or no access to gene therapies. Currently in preclinical stage, IMM-4800 has exceptional drug-like properties differentiating it from other BACH1 inhibitors and positioning it for success.

Anticipated milestones include IND enabling studies and Phase 1 clinical trials in 2026/27. Followed by Phase 2/3 trials and FDA approval submission leading to a transformative solution for Sickle Cell Disease worldwide.

BlueBloodCells.jpg

IMM–004 Systemic

Clinical Candidate

2026

IND

2026/27

Phase 1a/b

2026/27

Phase 2/3

TBD

Sickle Cell Disease (SCD)

Estimated Timelines

β-thal

PKD

Indication Expansion

Partnered with Novo Nordisk 

Sickle C

Pipeline Programs

IMM–002 Systemic

IMM–005 CNS

Renal / Metabolic

Partnered with Novo Nordisk 

Neurodegenerative

orangeGlow.jpg

Let's collaborate

Interested in partnering with us? Reach out to start the conversation
Immvention mark

© 2025 IMMvention Therapeutix

bottom of page